Patents Assigned to Macusight, Inc.
-
Publication number: 20100227879Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: ApplicationFiled: May 12, 2010Publication date: September 9, 2010Applicant: MacuSight, Inc.Inventors: Sreenivasu Mudumba, Philippe J.M. Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Publication number: 20090324686Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: July 29, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J.M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324689Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 13, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. COOPER, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324690Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 14, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324687Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: July 31, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324688Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 12, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. COOPER, David Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Patent number: 7585517Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: GrantFiled: September 20, 2004Date of Patent: September 8, 2009Assignee: Macusight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J M Dor, Sreenivasu Mudumba
-
Publication number: 20090074786Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: ApplicationFiled: August 18, 2008Publication date: March 19, 2009Applicant: MacuSight, Inc.Inventors: Philippe J.M. Dor, Sreenivasu Mudumba, Thierry Nivaggioli, David A. Weber, Sidiq Farooq, Sudeep K. Takhar
-
Publication number: 20060264453Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: ApplicationFiled: February 9, 2006Publication date: November 23, 2006Applicant: MacuSight, Inc.Inventors: Sreenivasu Mudumba, Philippe Dor, Thierry Nivaggioli, David Weber, Sidiq Farooq